Summary of Recent Settlements Novartis, Amgen and Boehringer Ingelheim
Discussion
In light of these cases, and in particular, the Novartis kickback case, Jose Sierra, a white collar lawyer who writes for the blog pharmarisc, proposed several factors for companies to consider.
Companies must ensure close monitoring of speaker programs to ensure compliance with internal policies and CIA requirements
For "front-end" controls, he recommends that companies should adopt a system in which no speaker program is scheduled without 6-10 "RSVPs" from invited doctors. "You need this many RSVPs because half the doctors never show up and 3-5 attendees are needed to pass the laugh test.Â...
Source: Policy and Medicine - July 19, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
Cardiology MCQ Online 5
Time limit: 0
Quiz-summary
0 of 25 questions completed
Questions:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
You are welcome to try this MCQ set and share it among your friends. Answer key with explanation appears after you complete the test and submit it and press on the view questions button. We strongly advise you t...
Source: Cardiophile MD - July 15, 2013 Category: Cardiology Authors: Prof. Dr. Johnson Francis MD, DM, FACC, FRCP Edin Tags: Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs
Cardiology MCQ Test 5
Cardiology MCQ Online 5
Time limit: 0
Quiz-summary
0 of 25 questions completed
Questions:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
You are welcome to try this MCQ set and share it among your friends. Answer key with explanation appears after you complete the test and submit it and press on the view questions button. W...
Source: Cardiophile MD - July 15, 2013 Category: Cardiology Authors: Prof. Dr. Johnson Francis MD, DM, FACC, FRCP Edin Tags: Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs
Chinese clinical trials probed
Published: July 14, 2013 3:00 a.m.Claims of sloppiness draw FDA’s interestDrew Armstrong | Bloomberg NewsNEW YORK – Drugmakers have increasingly been turning to China for large clinical trials because they’re cheaper and there’s a bigger population of subjects to draw on.Now U.S. regulators have stepped in, questioning sloppy data and irregularities from the world’s most populous country.Bristol-Myers Squibb Co. and Pfizer Inc.’s blood thinner Eliquis, approved in December, was stalled for nine months because of misconduct, errors and an alleged cover-up attempt at a Chinese trial site overseen b...
Source: PharmaGossip - July 14, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
More of Less is More
Some folks at BU review evidence about a diagnostic test, called CT pulmonary angiograms. (I think you can only read the abstract, but I shall summarize well.)A pulmonary embolism is a blockage in an artery in the lung. Sounds bad, right? And indeed it can be: symptoms can include respiratory distress, chest pain, and rapid heart beat and it can be fatal. The treatment is to take anticoagulant drugs, normally warfarin. This present a risk of bleeding but it beats dying. So we want to diagnose them all and make sure we don't miss any, right?That's what doctors thought to and they were accordingly delighted when CT scanning ...
Source: Stayin' Alive - July 8, 2013 Category: Health Medicine and Bioethics Commentators Source Type: blogs
